Alertas Bibliograficas – Endocrinología

Graves disease: latest understanding of pathogenesis and treatment options. Nat Rev Endocrinol. 
Lanzolla G, Marinò M, Menconi F. 
Published online July 22, 2024. 
doi:10.1038/s41574-024-01016-5

What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed MediatorsMulders MCF, de Herder WW, Hofland J.Endocr Rev. 2024 May 7;45(3):351-360. 
doi: 10.1210/endrev/bnad035

Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Mullen N, Curneen J, Donlon PT, et al.
Endocr Rev. 2024 Jan 4;45(1):125-170. 
doi: 10.1210/endrev/bnad026

Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
Kyriakie Sarafoglou, Mimi S Kim, Maya Lodish, et al.
N Engl J Med. 2024 Jun 2. 
doi: 10.1056/NEJMoa2404655

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Eystein S Husebye, Frederik Castinetti, et al. 
Eur J Endocrinol. 2022 Oct 25;187(6):G1-G21. 
https://doi.org/10.1530/EJE-22-0689

Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
Margaret C S Boguszewski, Cesar L Boguszewski , et al. 
Eur J Endocrinol. 2022 Apr 21;186(6):P35-P52. 
https://doi.org/10.1530/EJE-21-1186

Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop
John P Bilezikian 1, Aliya A Khan, et al. 
J Bone Miner Res. 2022 Nov;37(11):2293-2314. 
https://doi.org/10.1002/jbmr.4677